Skip to main content
OpenTrials
Completed

NCT Number: NCT01641276

Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma

The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Hepatocellular Carcinomas Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Sírio Libanês

São Paulo, 01308-050, Brazil

About this study

Patients will be exposed by different specific amplitude-modulated frequencies of low intensity electromagnetic fields for 30 min. During the exposure, autonomic response with be recorded in order to identify biofeedback response. Differences in group of frequencies is expected in patients with hepatitis B carries with or without hepatocellular carcinoma.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hepatitis B carriers patients
  • hepatitis B carriers patients with hepatocellular cancer patients

Exclusion criteria

  • other tumor types
  • other hepatitis types

Treatment and study plan

Low intensity amplitude-moduled electromagnetic fields

Device

Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.

Other names: TheraBionic, OncoBionic P1

Primary outcomes

  1. Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response

    Time frame: within 10 min of exposure

    biofeedback response will be monitored

Secondary outcomes

  1. Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma

    Time frame: within 10 minutes of exposure

    Representation of autonomous response during the exposure of specific frequencies of modulation

Sponsors and collaborators

Lead sponsor

Hospital Sirio-Libanes

Other

Registry information

Acronym: THBC-HSL2

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Jul 16, 2012
Registry last updated
Sep 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.